Abiomed (NASDAQ: ABMD) is a manufacturer of medical implant devices, including the AbioCor artificial heart and Impella. It is headquartered in Danvers, Massachusetts and has an additional office in Aachen, Germany. It has 800 employees worldwide. Michael R. Minogue joined Abiomed in 2004, and serves as CEO, Chairman and President. For fiscal year 2016, Abiomed reported $329.5 million in revenue, $65.1 million in operating income, $38.1 million in net income, $423 million in total assets, and $369 million in equity. Abiomed was founded in Danvers by David M. Lederman in 1981 as Applied Medical Corporation, and began working on the development of an artificial heart. Funded by federal research grants, Lederman partnered with The Texas Heart Institute to develop the AbioCor, implanting the first artificial heart into a Kentucky man in July 2001. Fourteen of the AbioCor devices were implanted, during clinical trials from 2001 to 2004, with the longest-living recipient surviving 512 days. The AbioCor won FDA approval in 2006 for patients who are near death and do not qualify for a heart transplant.